First trimester screening for Preeclampsia (PE) using FMF-London-Algorithm with placenta associated plasma protein-a (PAPP-A) and placental growth factor (PlGF)

C Birdir; A Enekwe; A Iannaccone; J Fryze; A Gellhaus; A Köninger; R Kimmig

doi:10.1055/s-0036-1587956

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000089.xml

Share / Bookmark

Facebook X Linkedin Weibo

Ultraschall Med 2016; 37 - P5_23
DOI: 10.1055/s-0036-1587956

First trimester screening for Preeclampsia (PE) using FMF-London-Algorithm with placenta associated plasma protein-a (PAPP-A) and placental growth factor (PlGF)

C Birdir ¹, A Enekwe ¹, A Iannaccone ¹, J Fryze ¹, A Gellhaus ¹, A Köninger ¹, R Kimmig ¹

¹University of Duisburg-Essen, Department of Obstetrics and Gynaecology, Essen, Germany

Congress Abstract

Purpose: To investigate the pregnancy outcomes of the high risk population after screening and off-label use of acetylsalicylic acid (ASA) 100 mg/day.

Materials and methods: 343 patients were screened between August 2013 and August 2015 using the FMF-London-Software combining the maternal history with multiple of the median (MoM) – Results of PlGF, PAPP-A, mean arterial pressure and pulsaltiliy index of uterine arteries.

Results: 40 patients (12%) were screened positive for early-onset PE with a cut-off of 1:150. 26 patients (84%) accepted a prophylactic off-label therapy with ASA 100 mg/day. Among these patients, 5 patients (19%) developed late-onset PE, 1 patient (4%) early-onset PE, 3 patients (12%) with intrauterine fetal growth retardation (IUGR) before 34 weeks and 2 patients (8%) with IUGR after 3 weeks.

Conclusion: The results of the multicenter ASPRE-Study need to be awaited to correlate our local results.